NHS England has approved a non-hormonal treatment for menopausal hot flushes and night sweats, as reported by the BBC. The drug, called Veoza, is a daily pill that blocks nerve pathways in the brain that trigger the symptoms.
According to Helen Knight, director of medicines evaluation at NICE, Veoza is an important additional option for those who cannot use hormone replacement therapy (HRT) due to underlying health conditions. Around 500,000 women could benefit from the drug.
The menopause can affect women's daily life in many ways, with hot flushes and night sweats being common symptoms. HRT is still the first-line treatment option, but Veoza provides an alternative for those who cannot use HRT.
Eligibility and Restrictions
Veoza can be used in cases of deep vein thrombosis (DVT) or pulmonary embolism, and in some cases of diabetes or heart disease when HRT isn't suitable. However, it is not recommended for women with breast cancer, other oestrogen-dependent cancers, or liver disease.
Approval and Availability
Veoza was approved in 2023, but has only now been recommended for treating moderate to severe symptoms of menopausal hot flushes and night sweats on the NHS by NICE. The decision applies in England, while Wales and Northern Ireland often follow the same NICE guidance.
Reaction from Healthcare Experts
Dr Sue Mann, national clinical director in women's health for NHS England, said the news was "very welcome", especially for women who are unable to take HRT or don't want to take it. She added that the drug could help hundreds of thousands of women experiencing menopause to manage their symptoms better and feel more in control of their health.
